Genistein ameliorates cardiac inflammation and oxidative stress in streptozotocin-induced diabetic cardiomyopathy in rats

Molecular and Cellular Biochemistry

Volumn 408, Issue 1-2, 2015, Pages 63-72

  Gupta, Suresh K ^a   Dongare, Shirish ^a   Mathur, Rajani ^a   Mohanty, Ipseeta Ray ^b   Srivastava, Sushma ^a   Mathur, Sandeep ^c   Nag, Tapas C ^c  

^a DELHI INSTITUTE OF PHARMACEUTICAL SCIENCES AND RESEARCH   (India)

^b MGM Medical College   (India)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Diabetic cardiomyopathy; Genistein; Inflammation; Oxidative stress

Indexed keywords

C REACTIVE PROTEIN; GENISTEIN; HEMOGLOBIN A1C; TRANSCRIPTION FACTOR RELA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; STREPTOZOCIN; TGFB1 PROTEIN, HUMAN; TNF PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDITIS; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC CARDIOMYOPATHY; GLUCOSE BLOOD LEVEL; HEART MUSCLE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT DURATION; WEIGHT CHANGE; ANIMAL; BLOOD; CARDIOMYOPATHIES; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CARDIOMYOPATHIES; DIABETES MELLITUS, EXPERIMENTAL; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION; GENISTEIN; HEMOGLOBIN A, GLYCOSYLATED; OXIDATIVE STRESS; RATS; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941997615     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2483-2     Document Type: Article

References (54)

1. Dhalla NS, Liu X, Panagia V, Takeda N (1998) Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 40:239–247
2. Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101:899–907
3. Guan SJ, Ma ZH, Wu YL, Zhang JP, Liang F, Weiss JW, Guo QY, Wang JY, Ji ES, Chu L (2012) Long-term administration of fasudil improves cardiomyopathy in streptozotocin-induced diabetic rats. Food Chem Toxicol 50:1874–1882
4. Falcao-Pires I, Leite-Moreira AF (2012) Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev 17:325–344
5. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867
6. Stratmann B, Tschoepe D (2011) The diabetic heart: sweet, fatty and stressed. Expert Rev Cardiovasc Ther 9:1093–1096
7. Ku PM, Chen LJ, Liang JR, Cheng KC, Li YX, Cheng JT (2011) Molecular role of GATA binding protein 4 (GATA-4) in hyperglycemia-induced reduction of cardiac contractility. Cardiovasc Diabetol 10:1–15
8. Wen HL, Liang ZS, Zhang R, Yang K (2013) Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol 12:1–11
9. Wang G, Li W, Lu X, Bao P, Zhao X (2012) Luteolin ameliorates cardiac failure in type I diabetic cardiomyopathy. J Diabetes Complicat 4:259–265
10. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17:189–212
11. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, Tschöpe C (2007) Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 6:500–507
12. Sara N, Edna S, Frederico P, Flávio R (2012) The role of inflammation in diabetic cardiomyopathy. Int J Infereron Cytokine Mediator Res 4:59–73
13. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067–2072
14. Patel S, Santani D (2009) Role of NF-kappa B in the pathogenesis of diabetes and its associated complications. Pharmacol Rep 4:595–603
15. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr, Wilson PW (2004) C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380–385
16. Goyal BR, Mesariya P, Goyal RK, Mehta AA (2008) Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Mol Cell Biochem 314:123–131
17. Shah SJ, Marcus GM, Gerber IL, McKeown BH, Vessey JC, Jordan MV, Huddleston M, Foster E, Chatterjee K, Michaels AD (2006) High-sensitivity C-reactive protein and parameters of left ventricular dysfunction. J Card Fail 12:61–65
18. Kardys I, Knetsch AM, Bleumink GS, Deckers JW, Hofman A, Stricker BH, Witteman JC (2006) C-reactive protein and risk of heart failure: the Rotterdam Study. Am Heart J 152:514–520
19. Border WA, Noble NA (1995) Fibrosis linked to TGF-beta in yet another disease. J Clin Invest 2:655–656
20. Khan R, Sheppard R (2006) Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 1:10–24
21. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, Klovekorn WP, Schaper J (2003) Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 7:984–991
22. Bugyei-Twum A, Advani A, Advani SL, Zhang Y, Thai K, Kelly DJ, Connelly KA (2014) High glucose induces Smad activation via the transcriptional coregulator p300 and contributes to cardiac fibrosis and hypertrophy. Cardiovasc Diabetol 13(89):1–12
23. Naderi GA, Asgary S, Sarraf-Zadegan N (2003) Anti-oxidant effect of flavonoids on the susceptibility of LDL oxidation. Mol Cell Biochem 246:193–196
24. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 12:5592–5595
25. Paradkar PN, Blum PS, Berhow MA, Baumann H, Kuo SM (2004) Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett 215:21–28
26. Park CE, Yun H, Lee EB, Min BI, Bae H, Choe W, Kang I, Kim SS, Ha J (2010) The antioxidant effects of genistein are associated with AMP-activated protein kinase activation and PTEN induction in prostate cancer cells. J Med Food 13:815–820
27. Gilbert ER, Liu D (2013) Anti-diabetic functions of soy isoflavone genistein: mechanisms underlying effects on pancreatic β-cell function. Food Funct 2:200–212
28. Nakajima M, Cooney MJ, Tu AH, Chang KY, Cao J, Ando A, An GJ, Melia M, de Juan E Jr (2001) Normalization of retinal vascular permeability in experimental diabetes with genistein. Invest Ophthalmol Vis Sci 42:2110–2114
29. Ramos JE, Al-Nakkash L, Peterson A, Gump BS, Janjulia T, Moore MS, Broderick TL, Carroll CC (2012) The soy isoflavone genistein inhibits the reduction in Achilles tendon collagen content induced by ovariectomy in rats. Scand J Med Sci Sports 5:e108–e114
30. Zeng X, Feng Y, Yang L, Huang Y, Zhou D, Sun J, Liu Y, Deng Y (2008) Single- and multiple-dose pharmacokinetics of genistein capsules in healthy chinese subjects: a phase I, randomized, open-label study. Curr Ther Res Clin Exp 4:318–333
31. Fouad AA, Al-Sultan AI, Yacoubi MT, Gomaa W (2010) Ameliorative effects of telmisartan in diabetic rats with indomethacin-induced gastric ulceration. Eur J Pharmacol 637:162–170
32. Yang W, Wang S, Li L, Liang Z, Wang L (2011) Genistein reduces hyperglycemia and islet cell loss in a high-dosage manner in rats with alloxan-induced pancreatic damage. Pancreas 40:396–402
33. Fu Z, Zhang W, Zhen W, Lum H, Nadler J, Bassaganya-Riera J, Jia Z, Wang Y, Misra H, Liu D (2010) Genistein induces pancreatic beta-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinology 151:3026–3037
34. Elmarakby AA, Ibrahim AS, Faulkner J, Mozaffari MS, Liou GI, Abdelsayed R (2011) Tyrosine kinase inhibitor, genistein, reduces renal inflammation and injury in streptozotocin-induced diabetic mice. Vasc Pharmacol 55:149–156
35. Lee JS (2006) Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. Life Sci 79:1578–1584
36. Guo TL, Germolec DR, Zheng JF, Kooistra L, Auttachoat W, Smith MJ, White KL, Elmore SA (2014) Genistein protects female nonobese diabetic mice from developing type 1 diabetes when fed a soy- and alfalfa-free diet. Toxicol Pathol (Apr 8. [Epub ahead of print] PubMed PMID: 24713318)
37. Behloul N, Wu G (2013) Genistein: a promising therapeutic agent for obesity and diabetes treatment. Eur J Pharmacol 698:31–38
38. Nemoto O, Kawaguchi M, Yaoita H, Miyake K, Maehara K, Maruyama Y (2006) Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ J 70:327–334
39. Van Linthout S, Spillmann F, Riad A, Trimpert C, Lievens J, Meloni M, Escher F, Filenberg E, Demir O, Li J, Shakibaei M, Schimke I, Staudt A, Felix SB, Schultheiss HP, De Geest B, Tschope C (2008) Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 117:1563–1573
40. Sun D, Shen M, Li J, Li W, Zhang Y, Zhao L, Zhang Z, Yuan Y, Wang H, Cao F (2011) Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3b dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol 10:1–8
41. Rajesh M, Mukhopadhyay P, Batkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horvath B, Mukhopadhyay B, Becker L, Hasko G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P (2010) Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol 56:2115–2125
42. Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D’Agostino RB Jr, Hamman RF, Dabelea D (2010) Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case–control study. J Clin Endocrinol Metab 95:2868–2876
43. Nian M, Lee P, Khaper N, Liu P (2004) Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94:1543–1553
44. Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, Leng L, Jiang Z (2011) Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int Immunopharmacol 6:762–768
45. Deodato B, Altavilla D, Squadrito G, Campo GM, Arlotta M, Minutoli L, Saitta A, Cucinotta D, Calapai G, Caputi AP, Miano M, Squadrito F (1999) Cardioprotection by the phytoestrogen genistein in experimental myocardial ischaemia-reperfusion injury. Br J Pharmacol 8:1683–1690
46. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, Richardson MA, Topper JN, Gimbrone MA Jr, Wrana JL, Falb D (1997) The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGF beta signaling. Cell 7:1165–1173
47. Kim YS, Kim NH, Jung DH, Jang DS, Lee YM, Kim JM, Kim JS (2008) Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. Eur J Pharmacol 594:18–25
48. s1−3. Am J Clin Nutr 68:1418S–1425S
49. Agarwal A, Nick HS (2000) Renal response to tissue injury: lessons from heme oxygenase-1 gene ablation and expression. J Am Soc Nephrol 5:965–973
50. Ryter SW, Kim HP, Nakahira K, Zuckerbraun BS, Morse D, Choi AM (2007) Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. Antioxid Redox Signal 9:2157–2173
51. Grieve DJ, Byme JA, Cave AC, Shah AM (2004) Role of oxidative stress in cardiac remodeling after myocardial infarction. Heart Lung Circ 13:132–138
52. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, Saitoh M, Fukui K, Fukuda I, Osanai T, Okumura K (2003) Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease: possible role for left ventricular remodeling. Eur Heart J 24:2180–2185
53. Molavi B, Mehta JL (2004) Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol 19:488–493
54. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213–3223